Kenvue Inc. (NYSE:KVUE – Get Free Report) has been given an average rating of “Hold” by the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $28.11.
A number of equities research analysts have recently issued reports on KVUE shares. HSBC started coverage on shares of Kenvue in a report on Thursday, June 1st. They issued a “hold” rating and a $27.00 price target on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Kenvue in a research note on Tuesday, May 30th. They issued a “hold” rating and a $27.00 target price on the stock. Bank of America started coverage on shares of Kenvue in a research note on Tuesday, May 30th. They issued a “buy” rating and a $30.00 target price on the stock. Citigroup lowered their target price on shares of Kenvue from $28.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, UBS Group began coverage on shares of Kenvue in a research note on Tuesday, May 30th. They issued a “neutral” rating and a $28.00 target price on the stock.
Kenvue Price Performance
Shares of Kenvue stock opened at $24.01 on Wednesday. Kenvue has a 12-month low of $22.49 and a 12-month high of $27.80. The company has a current ratio of 1.53, a quick ratio of 1.00 and a debt-to-equity ratio of 0.38. The stock has a 50-day moving average price of $25.76.
Kenvue Announces Dividend
The company also recently announced a dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, August 25th.
Insider Activity at Kenvue
In related news, Director Richard E. Allison, Jr. purchased 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The shares were acquired at an average price of $26.26 per share, for a total transaction of $525,200.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at approximately $525,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Institutional Trading of Kenvue
Several large investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC purchased a new position in Kenvue during the second quarter valued at $402,000. Byrne Asset Management LLC purchased a new position in Kenvue during the second quarter valued at $565,000. Baugh & Associates LLC purchased a new position in Kenvue during the second quarter valued at $2,019,000. Renaissance Capital LLC purchased a new position in Kenvue during the second quarter valued at $2,074,000. Finally, K.J. Harrison & Partners Inc purchased a new position in Kenvue during the second quarter valued at $2,632,000.
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.
Featured Stories
- Five stocks we like better than Kenvue
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
- Winners And Losers In The Oilfield Supercycle
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
